3 No-Brainer Stocks to Buy With $20 Right Now
Over multiple decades, Wall Street is nothing short of a bona fide wealth creator. But when examined over shorter timelines, it can be highly unpredictable. For instance, all three major stock indexes have oscillated between bear and bull markets in successive years since this decade began.…#nasdaqcomposite #siriusxmholdings #siriusxm #pandoramedia #tevapharmaceutical #copaxone #teva #suffice #kareschultz #pubmatic (Source: Reuters: Health)
Source: Reuters: Health - January 10, 2024 Category: Consumer Health News Source Type: news
FDA alerts patients, caregivers, and health care providers of cross-compatibility issues with autoinjector devices that are optional for use with glatiramer acetate injection
FDA is alerting patients, caregivers, and health care professionals that autoinjector devices that are optional for use with glatiramer acetate injection may not be compatible for use across FDA-approved glatiramer acetate injection drug products. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 18, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Patent infringement lawsuit filed against Natco by Johnson & Johnson, Momenta
Homegrown pharma firm Natco on Wednesday said Johnson& Johnson and Momenta Pharmaceuticals have filed a patent infringement lawsuit against the company and its marketing partner Mylan Pharmaceuticals Inc, along with others, in the US. Johnson& Johnson and Momenta Pharmaceuticals lawsuit alleges infringement of two old patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate injection, Natco said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 25, 2022 Category: Pharmaceuticals Source Type: news
Specialty Generics Face A Maze Of Perverse Incentives In Medicare Part D
Specialty generics haven't gained the kind of traction in Medicare Part D that one would expect. This includes specialty generics such as imatinib mesylate and glatiramer acetate. The current set-up of the Medicare Part D benefit sends the wrong price signals. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - January 4, 2021 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
Optimal Dose of Fingolimod for Multiple Sclerosis Confirmed Optimal Dose of Fingolimod for Multiple Sclerosis Confirmed
The 0.5-mg dose of fingolimod provides a greater reduction in annualized relapse rate vs both the 0.25-mg dose of fingolimod and the 20-mg dose of glatiramer acetate.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 17, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Prices of MS Medications Keep Soaring
WEDNESDAY, Jan. 15, 2020 -- The cost of essential medications for multiple sclerosis have nearly tripled this decade, despite the release of the first generic MS drug, a new study shows.
The 2015 release of glatiramer acetate -- the generic version... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 15, 2020 Category: General Medicine Source Type: news
Risk for Conversion of MS Varies With Different Therapies
WEDNESDAY, Jan. 16, 2019 -- For relapsing-remitting multiple sclerosis (MS), the risk for conversion to secondary progressive MS is lower with initial treatment with fingolimod, alemtuzumab, or natalizumab versus glatiramer acetate or interferon... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 16, 2019 Category: Pharmaceuticals Source Type: news
U.S. appeals court upholds ruling that canceled Teva Copaxone patents
A U.S. appeals court on Friday upheld a ruling that canceled patents owned by Teva Pharmaceutical Industries Ltd on its blockbuster multiple sclerosis drug Copaxone. (Source: Reuters: Health)
Source: Reuters: Health - October 12, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma
Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis
Mapi Pharma has completed an open-label Phase II clinical trial and is preparing to commence a pivotal Phase III clinical trial ... Biopharmaceuticals, Neurology, Acquisitions Mylan, Mapi Pharma, GA Depot, Glatiramer, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 10, 2018 Category: Pharmaceuticals Source Type: news
FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS
Glatopa 40 mg/mL joins already-approved Glatopa 20 mg/mL, a glatiramer acetate generic for treatment of relapsing forms of multiple sclerosis.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 15, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
Sandoz wins FDA nod for generic, injectable MS drug
Sandoz said today that the FDA has approved its Glatopa glatiramer acetate injection as a generic version of Copaxone to treat relapsing forms of multiple sclerosis.
The therapy, which is given three days per week, is administered using the Glatopaject injection device.
Get the full story at our sister site, Drug Delivery Business News.
The post Sandoz wins FDA nod for generic, injectable MS drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 13, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat Novartis sandoz Source Type: news
Teva planned for second generic Copaxone to enter market in 2018
TEL AVIV (Reuters) - Israel-based Teva Pharmaceutical Industries said on Tuesday it had anticipated and planned for a second generic competitor to its multiple sclerosis treatment Copaxone to enter the market in 2018. (Source: Reuters: Health)
Source: Reuters: Health - February 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
Sandoz announces US FDA approval and launch of Glatopa(R) 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL
Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched in the US in June 2015, will offer patients a compl... Biopharmaceuticals, Generics, FDA, Product Launch Sandoz, Novartis, Glatopa, glatiramer, Copaxone, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2018 Category: Pharmaceuticals Source Type: news
Teva warns on revenue amid tough US drug pricing
Israeli drugmaker’s shares drop as competition to top drug Copaxone bites (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - February 8, 2018 Category: Pharmaceuticals Source Type: news
Sclerosis medicine can fight multi-resistant bacteria
Encountering bacteria with innocent names such as Pseudomonas aeruginosa and Enterobacteriaceae can lead to hospitalisation and - in a worst-case scenario - can also be life-threatening. The bacteria, which cause infections such as pneumonia, frequently develop multi-resistance towards classic antibiotics. Researchers from Aarhus University have discovered that a drug known as glatiramer acetate, which is normally used for treating the disease multiple sclerosis, has a hitherto unknown effect on obstinate bacteria. (Source: World Pharma News)
Source: World Pharma News - November 22, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
